Literature DB >> 28615208

Deficiency of the NOD-Like Receptor NLRC5 Results in Decreased CD8+ T Cell Function and Impaired Viral Clearance.

Christopher R Lupfer1, Kate L Stokes1, Teneema Kuriakose1, Thirumala-Devi Kanneganti2.   

Abstract

Pathogen recognition receptors are vital components of the immune system. Engagement of these receptors is important not only for instigation of innate immune responses to invading pathogens but also for initiating the adaptive immune response. Members of the NOD-like receptor (NLR) family of pathogen recognition receptors have important roles in orchestrating this response. The NLR family member NLRC5 regulates major histocompatibility complex class I (MHC-I) expression during various types of infections, but its role in immunity to influenza A virus (IAV) is not well studied. Here we show that Nlrc5-/- mice exhibit an altered CD8+ T cell response during IAV infection compared to that of wild-type (WT) mice. Nlrc5-/- mice have decreased MHC-I expression on hematopoietic cells and fewer CD8+ T cells prior to infection. NLRC5 deficiency does not affect the generation of antigen-specific CD8+ T cells following IAV infection; however, a change in epitope dominance is observed in Nlrc5-/- mice. Moreover, IAV-specific CD8+ T cells from Nlrc5-/- mice have impaired effector functions. This change in the adaptive immune response is associated with impaired viral clearance in Nlrc5-/- mice. Collectively, our results demonstrate an important role for NLRC5 in regulation of antiviral immune responses and viral clearance during IAV infection.IMPORTANCE The NOD-like receptor family member NLRC5 is known to regulate expression of MHC-I as well as other genes required for antigen processing. In addition, NLRC5 also regulates various immune signaling pathways. In this study, we investigated the role of NLRC5 during influenza virus infection and found a major role for NLRC5 in restricting virus replication and promoting viral clearance. The observed increases in viral titers in NLRC5-deficient mice correlated with impaired effector CD8+ T cell responses. Although NLRC5-deficient mice were defective at clearing the virus, they did not show an increase in morbidity or mortality following influenza virus infection because of other compensatory immune mechanisms. Therefore, our study highlights how NLRC5 regulates multiple immune effector mechanisms to promote the host defense during influenza virus infection.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  MHC; NLR; NLRC5; Nod-like receptor; T cell; influenza A virus; lung; major histocompatibility complex; natural killer cell

Mesh:

Substances:

Year:  2017        PMID: 28615208      PMCID: PMC5553185          DOI: 10.1128/JVI.00377-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  A role for the human nucleotide-binding domain, leucine-rich repeat-containing family member NLRC5 in antiviral responses.

Authors:  Andreas Neerincx; Katja Lautz; Maureen Menning; Elisabeth Kremmer; Paola Zigrino; Marianna Hösel; Hildegard Büning; Robert Schwarzenbacher; Thomas A Kufer
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response.

Authors:  Y Sykulev; M Joo; I Vturina; T J Tsomides; H N Eisen
Journal:  Immunity       Date:  1996-06       Impact factor: 31.745

3.  NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways.

Authors:  Jun Cui; Liang Zhu; Xiaojun Xia; Helen Y Wang; Xavier Legras; Jun Hong; Jiabing Ji; Pingping Shen; Shu Zheng; Zhijian J Chen; Rong-Fu Wang
Journal:  Cell       Date:  2010-04-30       Impact factor: 41.582

4.  Rapid recovery of lung histology correlates with clearance of influenza virus by specific CD8+ cytotoxic T cells.

Authors:  C D Mackenzie; P M Taylor; B A Askonas
Journal:  Immunology       Date:  1989-07       Impact factor: 7.397

5.  NLRC5 interacts with RIG-I to induce a robust antiviral response against influenza virus infection.

Authors:  Priya Ranjan; Neetu Singh; Amrita Kumar; Andreas Neerincx; Elisabeth Kremmer; Weiping Cao; William G Davis; Jacqueline M Katz; Shivaprakash Gangappa; Rongtuan Lin; Thomas A Kufer; Suryaprakash Sambhara
Journal:  Eur J Immunol       Date:  2014-12-23       Impact factor: 5.532

6.  Cutting edge: impaired MHC class I expression in mice deficient for Nlrc5/class I transactivator.

Authors:  Amlan Biswas; Torsten B Meissner; Taro Kawai; Koichi S Kobayashi
Journal:  J Immunol       Date:  2012-06-18       Impact factor: 5.422

7.  NLR family member NLRC5 is a transcriptional regulator of MHC class I genes.

Authors:  Torsten B Meissner; Amy Li; Amlan Biswas; Kyoung-Hee Lee; Yuen-Joyce Liu; Erkan Bayir; Dimitrios Iliopoulos; Peter J van den Elsen; Koichi S Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-16       Impact factor: 11.205

8.  Eight-plasmid system for rapid generation of influenza virus vaccines.

Authors:  Erich Hoffmann; Scott Krauss; Daniel Perez; Richard Webby; Robert G Webster
Journal:  Vaccine       Date:  2002-08-19       Impact factor: 3.641

9.  Reduction of natural killer but not effector CD8 T lymphocytes in three consecutive cases of severe/lethal H1N1/09 influenza A virus infection.

Authors:  Laura Denney; Celia Aitken; Chris Ka-Fai Li; Eleri Wilson-Davies; Wai Ling Kok; Colin Clelland; Kevin Rooney; Duncan Young; Tao Dong; Andrew J McMichael; William F Carman; Ling-Pei Ho
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

10.  Inflammasome recognition of influenza virus is essential for adaptive immune responses.

Authors:  Takeshi Ichinohe; Heung Kyu Lee; Yasunori Ogura; Richard Flavell; Akiko Iwasaki
Journal:  J Exp Med       Date:  2009-01-12       Impact factor: 14.307

View more
  11 in total

Review 1.  Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.

Authors:  Saptha Vijayan; Tabasum Sidiq; Suhail Yousuf; Peter J van den Elsen; Koichi S Kobayashi
Journal:  Immunogenetics       Date:  2019-01-31       Impact factor: 2.846

Review 2.  MHC class I transactivator NLRC5 in host immunity, cancer and beyond.

Authors:  Steven X Cho; Saptha Vijayan; Ji-Seung Yoo; Toshiyuki Watanabe; Ryota Ouda; Ning An; Koichi S Kobayashi
Journal:  Immunology       Date:  2020-08-03       Impact factor: 7.397

3.  NLRC5 Serves as a Pro-viral Factor During Influenza Virus Infection in Chicken Macrophages.

Authors:  Shubhada K Chothe; Ruth H Nissly; Levina Lim; Gitanjali Bhushan; Ian Bird; Jessica Radzio-Basu; Bhushan M Jayarao; Suresh V Kuchipudi
Journal:  Front Cell Infect Microbiol       Date:  2020-05-19       Impact factor: 5.293

Review 4.  The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.

Authors:  Akhil Shukla; Maryse Cloutier; Madanraj Appiya Santharam; Sheela Ramanathan; Subburaj Ilangumaran
Journal:  Int J Mol Sci       Date:  2021-02-17       Impact factor: 5.923

Review 5.  Efficacy and Safety of "Three Chinese Patent Medicines and Three TCM Prescriptions" for COVID-19: A Systematic Review and Network Meta-Analysis.

Authors:  Shuo Zhang; Zhen Yang; Zhen-Lin Chen; Zhuo-Ning Li; Shi-Jun Yue; Jia-Jia Li; Yu-Ping Tang
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-12       Impact factor: 2.629

6.  SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis.

Authors:  Ji-Seung Yoo; Michihito Sasaki; Steven X Cho; Yusuke Kasuga; Baohui Zhu; Ryota Ouda; Yasuko Orba; Paul de Figueiredo; Hirofumi Sawa; Koichi S Kobayashi
Journal:  Nat Commun       Date:  2021-11-15       Impact factor: 14.919

7.  Identification of Nifurtimox and Chrysin as Anti-Influenza Virus Agents by Clinical Transcriptome Signature Reversion.

Authors:  Yijing Xin; Shubing Chen; Ke Tang; You Wu; Ying Guo
Journal:  Int J Mol Sci       Date:  2022-02-21       Impact factor: 5.923

8.  Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma.

Authors:  Lei Lv; Qinqin Wei; Zhiwen Wang; Yujia Zhao; Ni Chen; Qiyi Yi
Journal:  Front Bioeng Biotechnol       Date:  2021-07-09

9.  NLRC5: potential novel non-invasive biomarker for predicting and reflecting the progression of IgA nephritis.

Authors:  Yusa Chen; Huihui Li; Chenggen Xiao; Xiangli Zeng; Xiangcheng Xiao; Qiaoling Zhou; Ping Xiao
Journal:  J Transl Med       Date:  2018-11-19       Impact factor: 5.531

Review 10.  Hidden in plain sight: The effects of BCG vaccination in the COVID-19 pandemic.

Authors:  Eman A Toraih; Jessica A Sedhom; Titilope M Dokunmu; Mohammad H Hussein; Emmanuelle M L Ruiz; Kunnimalaiyaan Muthusamy; Mourad Zerfaoui; Emad Kandil
Journal:  J Med Virol       Date:  2020-12-17       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.